Kura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting

LA JOLLA, Calif. , June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from the ongoing Phase 2 clinical trial evaluating the efficacy, safety and biomarkers of tipifarnib in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) were selected for a poster presentation at the 14th International Conference on Malignant Lymphoma (ICML) being held June 14-17, 2017 in Lugano, Switzerland . In addition, Kura’s preliminary Phase 2 data in PTCL were also selected for a poster presentation at the 22nd Congress of the European Hematology Association (EHA) taking place June 22-25, 2017 in Madrid, Spain . Details for the Poster Presentation at ICML Title: Preliminary Results from an Open-label, Phase II Study of Tipifarnib in Relapsed or Refractory T-cell Lymphoma Presenter: Thomas E. Witzig , M.D., Mayo Clinic Abstract Number: 255 Date and Time: Wednesday, June 14, 2017 , poster may be viewed from Wednesday, June 14, 2017 at 12:00 CET through Friday, June 16, 2017 at 18:30 CET Location: Marquee Parco Ciani Details for the Poster Presentations at EHA Title: Preliminary Results from an Open-label, Phase II Study of Tipifarnib in Relapsed or Refractory T-cell Lymphoma Presenter: Thomas E. Witzig , M.D., Mayo Clinic Abstract Number: P571 Poster Session: EHA 22 Date / Time: Saturday, June 24, 2017 , 7:30 – 19:00 CET Location: IFEMA, Poster Area, Hall 7 In addition, data from a preclinical study of tipfarnib in T-cell leukemia by Dr. Mondejar (IDIVAL, Santander, Spain ) showing cell line sensitivity to common T leukemia mutations will be presented at EHA as an E-poster. Title: T-Cell Leukemia Sensitivity to Farnesyl Transferase Inhibition Using Tipifarnib Abstract Number: E834 Date / Time: Friday, June 23 , 09:30 CET through Saturday, June 24 , 19:30 CET Location: Poster Area, E-poster screens About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology , please visit the company’s website at www.kuraoncology.com . CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected] Kura Oncology, Inc. Tools Print RSS Feeds Email Alerts Footer Links - Top About Us Our Commitment The Story Behind Our Name Leadership Board of Directors Grants & Funding Investigator Sponsored Studies Compliance Declaration Our Approach Precision Medicines Overcoming Resistance Novel Biomarkers Pipeline Menin Inhibition Farnesyl Transferase Inhibitors Posters and Presentations Scientific Manuscripts Access to Investigational Drugs Outside a Clinical Study Patients & Caregivers Acute Leukemias Head & Neck Cancer Our Medicine Footer Links - Investors New Investors Overview Press Releases Events & Presentations Corporate Governance Financial Information Analyst Coverage FAQs Contact Footer Links - Careers Careers Values Life at Kura Benefits Open Positions Footer Links - News & Media News & Media Press Releases News & Perspecitives Expert Perspectives Media Resources 01 Footer Links - Contact Contact Kura Oncology, Inc. 4930 Directors Place, Suite 500 San Diego, CA 92121 (858) 500-8800 Kura Oncology, Inc. 2 Seaport Lane, Suite 8A Boston, MA 02210 (617) 588-3755 © 2026 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy | Cookie Policy | Consumer Health Data Scroll to top

The release as fetched from its publisher. kuraoncology.com ↗